Related Experiment Video

Updated: Jun 26, 2025

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia
03:22

Mechanical and Controlled PRP Injections in Patients Affected by Androgenetic Alopecia

Published on: January 27, 2018

15.1K

GLP-1 agonists and hair loss: a call for further investigation

Deesha D Desai1,2, Michelle Sikora1,3, Ambika Nohria1

  • 1The Ronald O. Perelman Department of Dermatology, New York University Grossman School of Medicine, New York, NY, USA.

International Journal of Dermatology
|May 14, 2024
PubMed

Insights

Glucagon-like peptide-1 (GLP-1) agonists, used for diabetes and obesity, have uncertain effects on hair health. Current clinical evidence is limited, necessitating careful patient monitoring for any hair-related side effects.

Area of Science:

  • Endocrinology
  • Dermatology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 (GLP-1) agonists are increasingly prescribed for type 2 diabetes mellitus (T2DM) and obesity.
  • The impact of GLP-1 agonists on hair health is debated, with theories suggesting both potential risks and benefits.

Purpose of the Study:

  • To review the current understanding and evidence regarding the effects of GLP-1 agonists on hair health.
  • To highlight the need for further research and clinical observation.

Main Methods:

  • Literature review of existing studies and theoretical propositions on GLP-1 agonists and hair health.
  • Analysis of proposed mechanisms, including effects on insulin sensitivity and scalp circulation.

Main Results:

  • Clinical evidence directly linking GLP-1 agonists to hair loss or altered hair growth is currently sparse.
  • Theoretical benefits include improved metabolic factors potentially supporting hair health, while theoretical risks involve disruption of hair growth cycles.

Conclusions:

  • The relationship between GLP-1 agonists and hair health requires further investigation.
  • Vigilant patient monitoring is crucial to identify and manage any potential adverse effects on hair during GLP-1 agonist therapy.
Keywords:
alopeciaglucagon‐like peptide‐1microvasculaturetelogen effluviumtype 2 diabetes mellitus

More Related Videos

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis06:41

A New Technique for Quantitative Analysis of Hair Loss in Mice Using Grayscale Analysis

Published on: March 9, 2015

9.0K
Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration10:09

Rapid Genetic Analysis of Epithelial-Mesenchymal Signaling During Hair Regeneration

Published on: February 28, 2013

13.7K

Related Concept Videos

Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
318
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
181
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
153
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors01:19

Oral Hypoglycemic Agents: α-Glucosidase Inhibitors

α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
173
Oral Hypoglycemic Agents: Biguanides and Glitazones01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
192
Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
257